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The low-density lipoprotein receptor (LDLR) and related
receptors are important for the transport of diverse biomol-
ecules across cell membranes and barriers. Their functions are
especially relevant for cholesterol homeostasis and diseases,
including neurodegenerative and kidney disorders. Members of
the LDLR-related protein family share LDLR class A (LA)
repeats providing binding properties for lipoproteins and other
biomolecules. We previously demonstrated that short linker
regions between these LA repeats contain conserved O-glycan
sites. Moreover, we found that O-glycan modifications at these
sites are selectively controlled by the GalNAc-transferase iso-
form, GalNAc-T11. However, the effects of GalNAc-T11–
mediated O-glycosylation on LDLR and related receptor local-
ization and function are unknown. Here, we characterized
O-glycosylation of LDLR-related proteins and identified con-
servedO-glycosylation sites in the LA linker regions of VLDLR,
LRP1, and LRP2 (Megalin) from both cell lines and rat organs.
Using a panel of gene-edited isogenic cell line models, we dem-
onstrate that GalNAc-T11–mediated LDLR and VLDLR O-gly-
cosylation is not required for transport and cell-surface expres-
sion and stability of these receptors butmarkedly enhances LDL
and VLDL binding and uptake. Direct ELISA-based binding
assays with truncated LDLR constructs revealed that O-glyco-
sylation increased affinity for LDL by 5-fold. The molecular
basis for this observation is currently unknown, but these find-
ings open up new avenues for exploring the roles of LDLR-re-
lated proteins in disease.
The low-density lipoprotein receptor (LDLR)3 and related
receptors are membrane-bound cell surface receptors with
important endocytic functions for lipoproteins and a variety of
diverse extracellular ligands (1). The foundingmember LDLR is
important formaintaining cholesterol homeostasis, and delete-
riousmutations in LDLR lead to decreased LDL catabolism and
elevated levels of plasma LDL-cholesterol (2). The LDLR super-
family includes the VLDL receptor (VLDLR), LDLR-related
protein 1 (LRP1), LDLR-related protein 1B (LRP1B), LDLR-
related protein 2 (LRP2 or megalin), and LDLR-related protein
8 (LRP8 or ApoER2), as well as more distantly related receptors
such as the sortilin-related receptor (1). These members also
have important roles in cardiovascular diseases, as well as
neurodegenerative and proteinuric renal diseases (3, 4). The
ectodomains of LDLR-related proteins share characteristic
structural features including LDLR-type A repeats (LA) (com-
plement-like cysteine-rich ligand binding repeats), epidermal
growth factor-like repeats, andTyr–Trp–Thr–Asp-propeller
domains (1).
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The LAmodules consist of40 amino acids each with three
disulfide bridges (Cys1–3, Cys2–5, and Cys4–6). They are found
as clusters of seven repeats in LDLR, eight in VLDLR, and mul-
tiple clusters in LRP1 and LRP2, and they constitute the domi-
nant ligand-binding region of these receptors (see Fig. 1) (5).
The functional structure of the LA module requires a calcium
ion coordinated by conserved acidic residues found between
Cys4 and Cys6 in the LA sequence, and binding to different
ligands appears to require different subsets of LA modules
(6–9). The LAmodules are bound by the ER-resident receptor-
associated protein (RAP) early in the secretory pathway, and
this interaction, believed to prevent premature intracellular
binding to ligands, is lost at lower pH such as in later Golgi
compartments (5, 9, 10). The LA modules are interspaced by a
short linker sequencemostly formed by four residues ending in
Thr with the sequence motif XXC6XXXTC1XX, although some
linkers are longer. Recently we demonstrated that the evolu-
tionary conserved Thr residues in these linkers of all LDLR-
related proteins carryO-glycans (11). Moreover, we found that
only one of the many polypeptide GalNAc-transferase (Gal-
NAc-T) isoenzymes, GalNAc-T11, which initiates O-glycosyl-
ation of proteins, was responsible for introducing O-glycans at
the Thr in the XXC6XXXTC1XX motif of linkers in LDLR and
presumably other receptors with this motif.
Both N- and O-glycosylation of LDLR have been reported
previously (7, 12).O-Glycosylation in the stem region is impor-
tant for cell-surface expression and stability of this receptor as
demonstrated with the CHO ldlD cell line deficient in the
UDP-Glc/GlcNAc C4-epimerase (12). Previous studies have
also suggested that O-glycosylation of LDLR in the N-terminal
domain may be important for LDL binding and uptake; how-
ever, the nature and positions of theseO-glycanswere not iden-
tified (13, 14). In the present study, we explored the functional
role of the identified O-glycans in the short linker regions
between LA modules (11). We took advantage of the finding
that theseO-glycans are specifically generated byGalNAc-T11,
whereas the O-glycans important for stability of LDLR on the
cell membrane are directed by multiple GalNAc-Ts (11). Using
genetically engineered human HepG2 and HEK293 cells, as
well as Chinese hamster ovary (CHO) cells, we demonstrate
that the O-glycans in the LA ligand-binding region of LDLR,
as well as VLDLR, are important for high-affinity lipoprotein
binding and uptake and that the sialic acids carried by these
O-glycans are essential for this. These findings have important
implications for our understanding of the function and regula-
tion of the LDLR-related proteins and their roles in diseases.
Results
O-Glycosites in the linker regions of class A repeats of
LDLR-related proteins
We have previously identified a total of 17 O-glycosylation
sites in evolutionary conserved linker regions in between LDLR
LA repeats within the sequence motif XXC6XXXTC1XX of
most of the LDLR-related proteins in a large number of engi-
neered human SimpleCells (SCs) (Fig. 1, labeled 1) (15–17). SCs
are genetically engineering cell lines with knockout of the
COSMC gene, which is an essential chaperone for the core1
synthase, C1GALT1, that elongates the initial O-GalNAc gly-
cans in most cell types. Thus, the O-glycan structures in SCs
have the rather homogeneous GalNAc or in some cells
NeuAc2,6GalNAc structures facilitating sensitive identifica-
tion by MS using lectin enrichment of glycopeptides in cell
digests (15). The identified O-glycosites in LDLR-related pro-
teins include two of the fourXXC6XXXTC1XXmotifs in LDLR,
two of five in VLDLR, two of two in LRP8, five of eight in LRP1,
one of six in LRP1B, and seven of thirteen in LRP2. Additional
O-glycosites in linker regions with slightly different sequences
were also identified (Fig. 1, linkers shown in red). Analysis of
LDLR in HEK293 and CHO cells suggested that recombinant
shed LDLR had partial occupancy of O-glycans in the LA
regions, whereasO-glycosylation of the juxtamembrane region
was more complete (11).
The SimpleCell glycoproteomics strategy involves genetic
truncation ofO-glycosylation for efficient enrichment and sen-
sitiveMSsequencing, andherewe first sought to confirmO-gly-
cosylation of the linker regions in LDLR-related proteins inWT
cells and rat organs. We previously did confirm some of the
LDLR, VLDLR, and LRP1 sites inWTCHO cells (18), as well as
in rat liver and human plasma (19) (Fig. 1, labeled 2 and 3, and
Data Set S1).We extended these studies to include comprehen-
sive analysis of LDLR-related proteins in rat liver, brain, and
kidney (Fig. 1, labeled 4, and Data Set S2), and we were
able to confirm four of the four predicted glycosites in the
XXC6XXXTC1XX linker regions of LDLR, three of five in
VLDLR, seven of eight in LRP1, and eight of ten in LRP2 (rat
LRP2 has three fewer predicted glycosites than human between
LA1–2, 23–24, and 30–31).
To further confirm theseO-glycans, we analyzed LRP2 puri-
fied from rat kidney. The neuraminidase-treated and trypsin-
digested LRP2 yielded coverage of57% of the ectodomain of
LRP2 (Data Set S4). We identified 11 O-glycosites with six
found in the 10 XXC6XXXTC1XX motifs (Fig. 1 and Data Set
S4). In most cases the corresponding peptides without O-gly-
cans were also identified, which may suggest incomplete stoi-
chiometry in agreement with our previous studies of secreted
LDLR, although the purified LRP2 may include intracellular
immature glycoforms (11).
Trafficking and cell-surface expression of LDLR is not
dependent on GalNAc-T11
It is well established that LDLR requires O-glycosylation in
the stem region for stability at the cell surface (12), so we first
established that surface expression of LDLR in human liver
HepG2 cells was unaffected by the loss of GalNAc-T11–
mediated O-glycosylation of the linker regions. Knockout of
GALNT11 or the COSMC chaperone required for the core 1
synthase C1GALT1 to truncateO-glycans to the initial GalNAc
residue in HepG2 cells did not affect expression, trafficking, or
shedding of the endogenous LDLR, as evaluated by SDS-PAGE
Western blotting analysis of total cell lysates (Fig. 2A) and 35S-
labeled pulse-chase experiments (Fig. 2B). Flow-cytometric
analysis of nonpermeabilized HepG2 cells further confirmed
that the cell-surface expression of endogenous LDLRwas unaf-
fected by the loss of GalNAc-T11–mediatedO-glycosylation or
capacity for elongation of O-glycans (Fig. 2C).
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Interestingly, the general truncation of O-glycans to the
unsialylated GalNAc residue by COSMC knockout in HepG2
cells (20) did not appear to affect cell surface stability or shed-
ding of the LDLR (Fig. 2C). This is, however, at least partly in
agreement with previous studies of LDLR shedding in the CHO
ldlD cell line, where complete loss ofO-glycosylation results in
rapid shedding and degradation of LDLR, whereas allowing
only GalNAc glycosylation by supplementing growth medium
with GalNAc alone at least partly retained cell-surface expres-
sion (20).
LDL ligand binding and uptake by LDLR is affected by
GalNAc-T11–mediated O-glycosylation
Fresh fluorescently labeled DiI-LDL was used in binding
anduptake studieswith isogenicHepG2 cellswith isogenic cells
with knockout of COSMC (SC), GALNT11, or GALNT2 (Fig.
Figure 1. Graphic depiction of O-glycosites in LA linkers of human LDLR-related proteins. The depiction summarizes all identified O-glycosites (filled
yellow squares) and predicted O-glycosites (open squares) in LA linker regions of the LDLR family proteins. LA linkers with the relaxed sequence motif
XXC6XnTC1XX (n  3–5) are indicated as black lines, and other linkers are indicated with red lines. Glycosites previously identified in engineered human
SimpleCell lines (labeled 1) (15–17), in CHOWT cells (labeled 2) (18), in human plasma (labeled 3) (19), and in rat liver, kidney, and brain tissues (labeled 4) and
purified rat LRP2 (labeled 5) in the present study are shown. Detailed information aboutO-glycosites is presented in Data Set S1,O-glycopeptides identified in
the present study are described in Data Set S2, and (glyco)peptides identified in purified LRP2 are described in Data Set S4. Glycosites specifically regulated by
GalNAc-T11 (yellow and red squares) were identified by comparative analysis of isolated shed LDLR expressed in HEK293 SC cells with and without KO of
GALNT11 as previously reported (11) or by differential dimethyl-labelingO-glycoproteomics (17) of CHO andHEK293 SC cell lines (indicated) with andwithout
KO of GALNT11 in unpublished studies. Note that some LA modules are not conserved between rat and human (Table S1).
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3A). Initial assays were performed by exposing cells to 20g/ml
DiI-LDL for 4 h at 4 °C for binding and 37 °C for uptake, fol-
lowed by washing, air drying, fixation, and analysis by direct
fluorescent microscopy. Both binding and uptake of DiI-LDL
were substantially reduced in HepG2 cells with knockout of
COSMC and GALNT11, whereas knockout of the isoenzyme
control GALNT2 had no effect (Fig. 3A). Interestingly, knock-
out of COSMC or GALNT11 produced the same reduction,
suggesting that the elongated O-glycans with sialic acids are
required for the function.
We next performed a dose study (10–60g/ml) using FITC-
LDL and includingHepG2 cells with knockout of LDLR (Fig. 3B
and Fig. S2). A strong dose-dependent reduction of LDL bind-
ing and uptake was found in HepG2 cells withoutGANT11 and
COSMC, which was intermediary to the reduction found upon
knockout of the LDLR (Fig. 3B). Interestingly, both binding
Figure 2. Expression and shedding of LDLR is similar in HepG2WTandmutant cells. A, SDS-PAGEWestern blotting analysis of total cell extracts of HepG2
WT, SC, GALNT11 KO, and GALNT2 KO cell lines stained with anti-LDLR antibody (upper panel) and anti-calnexin (lower panel). The only immunoreactive band
corresponds to the expected migration of the mature form of LDLR (molecular mass, 160 kDa). A representative experiment of at least three is shown. B,
35S-pulse-chase analysis of shed LDLR from HepG2 WT and GALNT11 KO cells using immunoprecipitation with a polyclonal anti-LDLR antibody from culture
media. The signals were exposed in a PhosphorImager, and the only immunoreactive band corresponds to the expected migration of shed LDLR (molecular
mass, 97 kDa). The cellswerepulsed for 30minandchasedas indicated.A representative experimentof two is shown.C, flowcytometry analysis of LDLR surface
expression on nonpermeabilized HepG2 WT and mutant cells as indicated. A representative experiment of at least three is shown.
Site-specific O-glycosylation of LDLR and ligand interactions
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and uptake of FITC-LDL appeared to saturate at 40 g/ml in
HepG2 cells with deficiency in O-glycosylation, as well as in
LDLR, whereas saturation was not evident at 60 g/ml with
WT cells (Fig. 3B). We confirmed that these observations were
not cell type–specific by testing isogenic HEK293 and CHO
cells with similar knockouts (Fig. 4). Interestingly, knockout of
Ldlr in CHO cells produced a particularly pronounced reduc-
tion of binding and uptake of LDL compared with knockout of
Galnt11 or Cosmc (Fig. 4, C and D). Because truncation of
O-glycans by knockout of COSMC produced similar effects as
knockout of GALNT11, we tested the effect of sialic acid cap-
ping alone by pretreatment of cells with neuraminidase to
remove sialic acids on WT CHO and HepG2 cells and found
similar reduction in binding and uptake of FITC-LDL (Fig. 5).
In summary, these data indicate that sialic acid residues on
O-glycans in the LA linker regions directed by GalNAc-T11
enhance the capacity of LDLR for binding and uptake of LDL.
Recombinant LDLR ectodomains require O-glycans for
efficient inhibition of LDL binding and uptake byWT CHO cells
Weexpressed truncated secreted constructs of humanLDLR
in CHO cells with and without knockout of Galnt11 and iso-
lated them to apparent homogeneity (Fig. 6, A and B). The full
secreted ectodomains of LDLR, sLDLR, expressed inWTCHO
cells exhibited substantially better inhibition of FITC-LDL
uptake by HepG2 cells compared with the same construct
expressed in CHO cells without Galnt11 (Fig. 6C and Fig. S3).
Moreover, direct binding assays with LDL and sLDLR, as well
Figure 3. LDL binding and uptake is affected by GalNAc-T11O-glycosylation of LDLR in HepG2 cells. A, representative fluorescencemicroscopy images
of HepG2 cells after incubation with 20 g/ml DiI-LDL at 4 °C (upper panel) and 37 °C (lower panel) for 4 h. DiI-LDL– (red) and 4,6-diamino-2-phenylindole–
stained (DAPI) nuclei (blue) are shown. The scale bar indicates 10 m. HepG2 cells were grown for 24 h on gelatinized coverslips in LPDS medium prior to
treatment. At least three different experiments were performed. B, quantification of LDL binding (left panel) and internalization (right panel) of HepG2WT and
mutant cell lines cultured in 24wells with different concentrations of FITC-LDL at 4 or 37 °C for 4 h. The values represent themean of triplicate determinations
(n 3); error bars representS.D.
Site-specific O-glycosylation of LDLR and ligand interactions
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as a further truncated construct LA1–4, showed that the
constructs expressed in CHO without Galnt11 exhibited an
5-fold lower affinity compared with the same constructs
expressed inWT CHO cells (Table 1), emphasizing that loss of
O-glycosylation by GalNAc-T11 results in an LDLR that binds
LDL with much lower affinity.
VLDLR also require O-glycans for VLDL binding and uptake
VLDLR contains eight LA modules with five of the linker
regions predicted to carry O-glycans, although we have only
identified three of these yet with our shotgun glycoproteomics
strategy (Fig. 1). However, we have found in preliminary studies
that the two identified sites are dependent on GALNT11 in
CHO and HEK293 cells. We therefore tested binding and
uptake of FITC-VLDL by isogenic CHO cells with and without
knockout ofCosmc (SC) orGalnt11 (1C8 clone) and found that
loss of either gene resulted in substantial loss of binding and
uptake of VLDL, similar to what was found for LDL (Fig. 7).We
were unable to confirm cell-surface expression of VLDLR in
mutant cells because of a lack of antibodies, and we predict that
expression similar to LDLR is not affected by loss of GalNAc-
T11–mediated glycosylation (Fig. 2).
Conservation of GalNAc-T11–directed O-glycans in LA linkers
in Drosophila
Wepreviously demonstrated that theDrosophila ortholog of
GalNAc-T11, dGalNAc-T1 (dT1), or l(2)35Aa, is essential for
viability (21, 22).Drosophilamembers of the LDLR-related pro-
tein family consist of the lipophorin receptors (Lpr), which
share a similar organization of domains including seven or eight
LA modules (23). Lprs are essential for the efficient uptake of
neutral lipids in Drosophila and include Lpr1 and Lpr2, of
which Lpr2-E is the major receptor involved in the uptake by
nurse cells and oocytes (24). We expressed a C-terminal HA-
tagged full coding construct of Lpr2-E in WT CHO cells with
andwithoutKOofGalnt11, as well as the combination of KOof
Galnt11 and co-expression of dGalNAc-T1 (Fig. S4). The nat-
urally shed ectodomain of Lpr2-E without the HA tag was
Figure4.Analysis of theexpressionand functionof LDLRonCHOandHEK293WTandmutant cell clones.A, SDS-PAGEWesternblotting analysis of LDLR
expressed in CHO (left panel) and HEK293 (right panel) cells using anti-LDLR antibody (Ab30532, Abcam). Analysis of calnexin expression in HEK293 cells was
evaluatedwith anti-calnexin (ADI-SPA-860) specific for the humanprotein. Equal amounts of cell lysate protein based on BCAwere loaded, and the blots show
a representative example from at least three repeat experiments. Bands labeled with stars were considered unspecific. B, FACS analysis of uptake of two
concentrations of FITC-LDL by HEK293WT and GALNT11 KO cells at 37 °C for 4 h. The experiment was performed twice with similar results, and representative
results are shown. C, FACS analysis of binding of FITC-LDL by CHOWT, SC, andGalnt11 KO cells 4 °C for 4 h.D, FACS analysis of uptake of FITC-LDL by CHOWT,
SC, andGalnt11KOcells at 37 °C for 4 h. The experiments inC andDwere performed in triplicate (n 3), and the data shown represent averageswith error bars.
Site-specific O-glycosylation of LDLR and ligand interactions
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enriched by Jacalin chromatography of glycoproteins with
sialylated ST (NeuAc2–3Gal1–3GalNAc1-O-Ser/Thr)
O-glycans followed by trypsin digestion and direct LC-MS/MS
analysis without prior neuraminidase treatment. We obtained
an overall sequence coverage for Lpr2-E of 45%with the sample
from CHO WT and CHO Galnt11 KO and 35% from CHO
Galnt11KOwith the co-expression of dGalNAc-T1. The linker
region (LA2–3) with the consensusmotif C6RSHTC1was iden-
tified as glycopeptide only in CHO cells with expression of
human GalNAc-T11 (WT) or co-expression of Drosophila
dGalNAc-T1, whereas in CHOGalnt11 KO, we only identified
the corresponding unglycosylated peptide (Fig. 8 and Data Set
S3). These results suggest that the mammalian and Drosophila
orthologs share the unique capabilities in glycosylating LDLR-
related protein linker regions.
Discussion
Protein O-glycosylation of the GalNAc-type serves diverse
and highly specific roles in fine-tuning protein functions (25),
and here we provide conclusive evidence for a novel role in
modulating the binding properties of the large family of LDLR-
related proteins. Other types of proteinO-glycosylation includ-
ing O-Fuc, O-Glc, and O-GlcNAc modulate the binding prop-
erties and signaling of the Notch receptors, and these types of
glycosylation serve important roles in development and dis-
eases (26). GalNAc-typeO-glycosylation is unique and orches-
trated by a large family of isoenzymes that enables differential
and perhaps dynamic regulation of single glycosites. The spe-
cificmodification of the LA linkers in LDLR-related proteins by
the GalNAc-T11 isoform presented here is perhaps the most
exclusive function of a GalNAc-T isoenzyme identified to date.
We show that GalNAc-T11 directedO-glycosylation of the LA
linkers in the ligand-binding domains of LDLR and VLDLR
markedly affect the binding affinity and uptake of their respec-
tive lipoprotein targets, and it is likely that this is a general
function for all LDLR-related proteins.
Our results are in agreement with and extend early studies
suggesting the existence of O-glycans in addition to the well
characterized glycans in the juxtamembrane region of LDLR
(27), and they may provide an explanation for the otherwise
puzzling finding that a Monensin-resistant CHO line, MonR-
31, with apparent loss of these glycans showed reduced binding
and uptake of LDL (13, 14, 28). TheMonR-31 cell line is unfor-
tunately no longer available, but our results suggest that the
lectin selection used to establish the cell line resulted in deletion
of the GALNT11 gene. Studies over decades with lectin-resist-
ant CHO mutants demonstrate that the O-glycans in the jux-
tamembrane region of LDLR are essential for stability of the
receptor at thecell surface (12), but importantlyO-glycosylation in
the juxtamembrane “mucin-like” domain with high density of
O-glycans is redundantly achieved by multiple GalNAc-T iso-
Figure 5. Analysis of effect of neuraminidase pretreatment on LDL uptake. HepG2 WT cells (A) and CHO WT cells (B) were pretreated with and without
neuraminidase and subjected to lectin immunocytology (upper panels) and FITC-LDL binding assays (lower panels). PNA andMaackia amurensis lectin II (MAL
II) lectinswere used to demonstrate the loss of sialic acids by the neuraminidase treatment. FACS analysis of FITC-LDL bindingwas performedwith HepG2 and
CHO WT and SC cells, and pretreatment with neuraminidase affected binding to WT cells but not to SC cells, which is in agreement with the established
O-glycosylation capacity of these cells whereWT produces sialylated core 1O-glycans, and SC produces the nonsialylated GalNAcO-glycans. The experiment
was performed twice with similar results.
Site-specific O-glycosylation of LDLR and ligand interactions
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forms and presumably not regulated (11). In contrast, the single
O-glycosites in the LA modules are selectively controlled by the
GalNAc-T11 isoform and therefore amenable to differential and
perhaps dynamic site-specific regulation in cells and organs.
It is increasingly becoming apparent that site-specific regu-
lation of selectedO-glycosites by the large family of GalNAc-T
isoenzymes are involved in fine-tuning protein function with
important roles in health and diseases (25). The most illustra-
tive example to date is the unique role of the GalNAc-T3 iso-
form in phosphate homeostasis, whereO-glycosylation co-reg-
ulates proprotein processing of FGF23 in a complex interplay
with proprotein convertases and the Golgi protein kinase
Fam20C, within the short sequence element 176RHTR2S,
whereO-glycosylation of Thr178 directed by GalNAc-T3 inhib-
its processing and phosphorylation of Ser181 by Fam20C inhib-
its O-glycosylation (29, 30). Congenital deficiency in GALNT3
cause hyperphosphatemia and ectopic ossifications, whereas
deficiency in Fam20C causes osteosclerotic dysplasia and
hypophosphatemia (31, 32), and GALNT3 is a GWAS candi-
date for low mineral bone density (33). Many of the other 20
GALNT genes have been identified as candidate genes for dis-
positions to common diseases (25, 34), and we were recently
able to provide extensive validation for the role of GALNT2 in
Figure 6. Analysis of truncated LDLR constructs and inhibition of LDL uptake. A, graphic depiction of truncated LDLR constructs sLDLR and LA1–4 used.
B, SDS-PAGE Coomassie and Western blotting analyses of purified sLDLR and LA1–4 using anti-LDLR (Abcam, Ab30532) or anti-His. sLDLR and LA1–4 were
expressed in CHO cells and purified using Jacalin lectin chromatography or nickel–nitrilotriacetic acid, respectively, and further purified by ion exchangewith
a yield of30 g from 100 ml of growth medium. The presence of two molecular weight forms of sLDLR is likely due to N-terminal truncation as reported
previously (57). Note minor differences in migration of sLDLR and LA1–4 derived from cells with and without Galnt11, presumably because of a loss of
O-glycans at the three glycosites in the linker region (Thr67, Thr108, and Thr147). Loading was based on BCA quantification of purified proteins, but the yield of
sLDLR isolated from cells with knockout of Galnt11 appeared higher based on the Coomassie staining andWB. C, quantification of FITC-LDL uptake by HepG2
WT cells in the presence of sLDLR with and withoutO-glycans introduced by GalNAc-T11. 20g/ml FITC-LDL was preincubated with different concentrations
of sLDLR as indicated (based on the BCA quantification) and subsequently incubated with HepG2WT cells for 1 h at 37 °C. The values represent the means of
triplicate determinations (n 3); error bars represent S.D.
Table 1
ELISA-based binding analysis of the interaction between LDLR frag-
ments and LDL
EC50 (meansS.D.) N
nM
sLDLRWT 4.52 1.25a 4
sLDLR T11KO 30.61 5.06 4
LA 1–4 WT 16.76 2.4 3
LA 1–4 T11KO 73.98 15.44 3
a The value is in good agreement with previously reported values in the nM range
(55, 58).
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Figure 7. Analysis of FITC-VLDL binding and uptake in CHOWT andmutant cell lines. CHOWT, SC, and Galnt11 KO (1C8 clone) were incubated with two
different concentrations of FITC-VLDL (20 or 50 g/ml) at 4 °C for binding (left panel) or 37 °C for internalization (right panel) for 4 h. The FACS analysis and
quantification was performed as described in the legend to Fig. 4. The experiment was performed twice with similar results, and a representative data set is
presented.
Figure8. Extracted ion chromatographs (XICs) of the identifiedglycopeptides andpeptides at theLA2–3 linkerof Lpr2-E. LC–MS/MSdata of the tryptic
digest of the lectin enriched O-glycoproteins from Lpr2-E expressing CHO WT (top panel), CHO Galnt11 KO (middle panel), and CHO Galnt11KO with stable
expression of dGalNAc-T1 (bottom panel) were extracted with the theoreticalm/z of the identified linker region glycopeptides and peptides. XICs of different
ionic forms of the identified peptide sequence with or without one of the predicted glycans (HexNAc, HexNAcNeuAc, HexHexNAc, and HexHexNAcNeuAc)
were used for search. The identified glycoforms are annotated, and XIC peaks are labeled with the accuratem/z of the (glyco)peptides and charge states.
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dyslipidemia in man, primates, and rodents and identified sev-
eral site-specifically regulatedO-glycoprotein targets (19). The
substrate specificities and functions of GalNAc-Ts havemainly
been studied by in vitro enzyme assays using short peptides as
acceptors in the past (35), and this approach has provided
important insights into specific functions of many individual
isoenzymes including GalNAc-T11. However, although Gal-
NAc-T11 does function with a number of short peptide sub-
strates (21, 22, 35), it only functions in vitro with the LA linker
regions in the context of the entire folded LA-modules (11).
This may suggest that GalNAc-T11 is unique among the Gal-
NAc-T isoforms in recognizing folded domains as substrates.
Other glycosyltransferases initiating O-Fuc, O-Glc, and O-
GlcNAc recognize small folded domains such as epidermal
growth factor-like and thrombospondin type 1 repeats (26, 36),
and these domains share a design with three conserved disul-
fide bridges with the LAmodules (37, 38). However, in all cases
the acceptor sites are located in the folded domain, whereas the
substrate site for GalNAc-T11 is located in the short linker
between the folded domains. We only discovered the unique
function of GalNAc-T11 throughO-glycoproteomics with gly-
coengineered cell lines (11). Availability of isogenic cell lines
with and without individual GALNT genes are important dis-
covery platforms for the isoform-specific functions as shown
here and in combination with our quantitative differential gly-
coproteomics approach enable unbiased discovery of nonre-
dundant biological functions of the large family of GalNAc-T
isoenzymes (17). We also used genetic dissection to demon-
strate the functional importance of the structure of the O-gly-
cans. Thus, knockout of COSMC in CHO and HepG2 cells,
which results in truncation of the normal core1 O-glycans to
the simple GalNAc residue, produced the samemarked change
in the function of LDLR, demonstrating the importance of the
O-glycan structure and the terminal sialic acid (Figs. 3–5).
Cellular trafficking of LDLR-related proteins is complex and
essential for their functions. These receptors are transported
through the ER-Golgi secretory pathway bound to the recep-
tor-associated protein RAP (LRPAP1 or 2-macroglobulin
receptor-associated protein) that acts as a chaperone and pre-
sumably protect receptors from early binding to ligands until
dissociation occurs at the lower pH in later Golgi compart-
ments (39). Studies with Escherichia coli produced LAmodules
without glycans established that RAP binds to multiple LA
modules through electrostatic interaction between three calci-
um-coordinating acidic residues in each LA and lysine residues
(9, 40, 41). In LRP1 the most juxtamembrane cluster of LA
modules LA3–6 that contains linker O-glycans (Fig. 1 and
Table S1) appears to be the most important (9, 41). In a recent
study of the complete LRP1 protein expressed in HEK293 cells,
presumably withGalNAc-T11 directedO-glycosylation, strong
nanomolar interaction with RAP was demonstrated (42), sug-
gesting that O-glycosylation of the linkers in LA modules may
not play a role in the interaction with RAP, which is also in line
with our finding that surface expression and shedding of LDLR
was unaffected by LAmoduleO-glycosylation (Fig. 2,A andC).
The co-crystal structure of RAPwith the LAmodules 3 and 4 in
a complex shows that the acceptor Thr in the LA linker region
is facing toward RAP at a distance of 10 Å from the closest
amino acid of RAP (9), suggesting that O-glycosylation may
occur only after release from RAP.
The ligand binding of LDLR-related proteins resembles the
interaction with RAP and depends on the conserved acidic res-
idues in the LAmodules (9). Many studies of the ligand binding
properties of LDLR and VLDLR have been performed with
E. coli produced truncated receptor constructs (43–45), which
would exclude analysis of theO-glycans found in the LA linkers.
Similarly, studies with LDLR expressed in insect cells are likely
to exclude these O-glycans or at least completely lack sialic
acids (9). However, the O-glycans are not essential for binding,
but they induce amarked enhancement in extracellular binding
and uptake of LDL and VLDL by LDLR and VLDLR in cell
assays. This was clearly shown for LDLR in CHO cells, where
deficiency in O-glycans produced intermediary LDL binding
and uptake compared with complete LDLR deficiency and fur-
ther supported by direct binding assays showing detectable but
5-fold lower binding affinity of sLDLR to LDL in the absence
ofO-glycans (Fig. 4,C andD, andTable 1).HowO-glycans exert
these effects requires structural studies with appropriately gly-
cosylated receptor constructs, but we envision that the sialy-
lated O-glycans may participate directly in the ligand interac-
tion by, for example, adding to the negative charges of the
conserved aspartic acids in the LA module or perhaps more
likely induce local conformational effects that organize consec-
utive LA modules in more favorable binding mode.
The implications of our findings for the many diseases and
conditions associated with the diverse functions of LDLR-re-
lated proteins require further studies. Genetic deficiency in
GALNT11 has not been identified so far in man, and it is pre-
dicted to be extremely rare if occurring (34), butGALNT11 has
been identified as a GWAS candidate gene for chronic kidney
decline (46). The GWAS signal for chronic kidney decline
resides in intron one of theGALNT11 gene, suggesting that the
genetic predisposition is a result of altered gene regulation, sim-
ilar to what has been established for the role of GALNT2 in
dyslipidemia (19, 47). Our study did not directly address the
functional role of O-glycans on other LDLR-related proteins
including LRP2; however, GalNAc-T11 is highly expressed in
proximal tubules of the kidney, andLRP2 is themajor endocytic
receptor responsible for reabsorbtion of proteins from the glo-
merular filtrate (21, 48). Given the common structure of the
ligand binding LA modules and conservation of LA linker
O-glycan sites directed by GalNAc-T11, we propose that the
O-glycans on all the LDLR-related proteins serve similar roles
inmodulating ligand binding.Moreover, it seems plausible that
the identification of GALNT11 as a GWAS candidate for
chronic kidney disease may relate to altered glycosylation and
function of LRP2, and further studies into this are clearly war-
ranted. Given the important roles of LDLR and VLDLR in lipo-
protein metabolism and hypercholesterolemic conditions (49)
and the dramatic effect GalNAc-T11 directed O-glycosylation
has on these receptors, it may be surprising thatGALNT11 has
not been associated with cholesterol disorders. We are in pro-
gress with such studies, but we did provide evidence that the
unique substrate specificity of GalNAc-T11 is at least partially
conserved by the Drosophila ortholog dGalNAc-T1 also desig-
nated l(2)35Aa, which is essential for viability (21, 22). In sum-
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mary, our study presents conclusive evidence for an important
functional role of O-glycans in modulating the ligand binding
propertiesof the large familyofLDLR-relatedproteins,whichpro-
vides a novel understanding of the function and potentially regu-
lation of these receptors with wide implications for common
diseases.
Experimental procedures
O-Glycoproteomic analysis of rat organs
Samples of100 mg of tissue from rat liver, brain, or kidney
were homogenized in 300 l of lysis buffer containing 1%
RapiGest (Waters) in 50 mM ammonium bicarbonate using an
IKA Ultra Turbax blender at maximum speed for 20 s followed
by 30 s of sonication using a Sonic Dismembrator (Fischer Sci-
entific). Homogenates were boiled for 5 min, diluted with 50
mM ammonium bicarbonate to 0.1% RapiGest, reduced with 20
mMDTT in 50mM ammonium bicarbonate at 60 °C for 45min,
alkylated with 40 mM iodoacetamide in 50 mM ammonium
bicarbonate at room temperature for 35 min, followed by addi-
tion of 20 mM DTT to terminate alkylation, and digestion with
trypsin (50 g/sample) (Roche) at 37 °C, ON. Digests were
treated with concentrated 6l TFA at 37 °C for 30min, cleared
by centrifugation, and purified on C18 Sep-Pak (Waters). The
digests were desialylated with 1 unit of neuraminidase (N3001,
Sigma) in 50 mM sodium citrate (pH 5.0) at 37 °C overnight
followed by SepPak purification and lyophilization. The sam-
ples were dissolved in lectin-binding buffer (175 mM Tris, pH
7.4) and subjected to Jacalin-agarose (AL1153, Vector Labora-
tories) lectin weak affinity chromatography (LWAC) per-
formed as described previously with PNA (19), with minor
modifications. The glycopeptides were eluted with 3  1-col-
umn volume 0.7 M galactose in lectin buffer (175 mM Tris,
pH 7.4). Lectin weak affinity chromatography fractions were
screened by LC-MS for glycopeptide content, and fractions
enriched in glycopeptides were pooled and submitted to
LC-MS analysis using EASY-nLC 1000 UHPLC (Thermo Sci-
entific) interfaced via NanoSpray Flex ion source to an LTQ-
Orbitrap Fusion Pro spectrometer (Thermo Scientific), as pre-
viously described (17). Data processing was performed using
Proteome Discoverer 1.4 software (Thermo Scientific).
Gene targeting of GALNT11and LDLR in HepG2 cells
A CompoZTM custom zinc finger nuclease targeting con-
struct for GALNT11 with the following binding and cutting
(parentheses) sites, 5-GACCGCTTGGGCTAC(CACAGA)
GATGTGCCAGACACAAGG-3 was obtained from (Merck
Millipore) and GFP/Crimson-tagged as previously described
(50). Guide RNAs targeting exon2 of LDLR was designed using
a gUIDEbookTM, Desktop Genetics-Horizon Discoveries
gRNA design algorithm and cloned into dual gRNA and
Cas9–2A-GFP expression vectorpX458 (Addgene plasmid no.
48138). Zinc finger nuclease or gRNA plasmids were trans-
fected into HepG2 cells by electroporation using Amaxa
Nucleofector (Lonza), and clones were selected using a work-
flowwith bulk sorting by FACS 48 h after transfection, followed
by 1–2 weeks in culture, and cloning by limiting dilution in
96-well plates as recently reported (51). Clones with frameshift
mutations were identified by Indel Detection by Amplicon
Analysis using the following primers (52): GALNT11-F, 5-
AGCTGACCGGCAGCAAAATTGTCGCTGACTAACTTC-
ACTCTTTTG-3; GALNT11-R, 5-TCTCAGACCATGTGG-
CTTCA-3; LDLR-F, 5-AGCTGACCGGCAGCAAAAT-
TGGATTCTGGCGTTGAGAGACC-3; and LDLR-R, 5-GT-
GCCTGTAATCCCAGCACT-3. All selected clones were
Sanger sequenced in the target site for confirmation (Fig. S1).
The HepG2 COSMC knockout and HepG2GALNT2 knockout
clones were described previously (17). All HepG2 clones were
grown in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 2 mmol/liter L-glutamine, and 1%
nonessential amino acids. All reagents for cell culture were
obtained from Gibco.
Expression and purification of secreted LDLR
A construct (LA1–4) containing residues 1–196 of the cod-
ing region of human LDLR was generated by PCR using a plas-
mid containing the entire coding region and cloned into
pcDNA3.1/myc-His (C-terminal tags) (Invitrogen). The fol-
lowing primers were used: LA-1-F, 5-CCCAAGCTTGCCAC-
CATGGGGCCCTGGGGCTGGAA-3; and LA-4-R, 5-CCG-
CTCGAGGGGGCTACTGTCCCCTTGGA-3. The plasmid
encoding LA1–4 and a bicistronic enhanced GFP (EGFP) plas-
mid encoding human full-length LDLR with a C-terminal V5
tag (53) were expressed in CHO WT and CHO Galnt11 KO
cells (1C8 clone). The sLDLR was purified as follows: after 48 h
of culture the medium (300 ml) was collected and dialyzed
twice against 50 mMTris (pH 7.4) at 4 °C, diluted into 2 bind-
ing buffer (350 mM Tris, pH 7.4), and applied to a 1-ml packed
Jacalin-agarose column (Vector Laboratories). Followingwash-
ing by 40–50 column volumes (CV) of binding bufferO-glyco-
proteins were eluted with 0.8 M galactose in binding buffer and
detected by Western blotting using anti-LDLR (ab30532,
Abcam). The secreted His-tagged LA1–4 construct was puri-
fied on nickel affinity chromatography (Invitrogen) by mixing
the culture media 3:1 (v/v) with 4 binding buffer (200 mM
Tris, pH8.0, 1.2MNaCl) and applied to 0.3ml of packed nickel–
nitrilotriacetic acid–agarose (Invitrogen) pre-equilibrated in
binding buffer (50mMTris, pH 8.0, 300mMNaCl). The column
was washed with binding buffer and eluted with binding buffer
containing 250 mM imidazole. Fractions containing LA1–4
were analyzed by SDS-PAGE and pooled. Further purification
of sLDLR and LA1–4 were achieved by anion-exchange
MonoQ (5/50 GL, GE Healthcare) chromatography on ÄKTA
FPLC interfaced by UNICORN 4.12 control software. Enriched
pooled fractions were centrifuged at 14,000 rpm at 4 °C for 30
min and loaded on the MonoQ pre-equilibrated in 25 mM Bis-
Tris (pH 6.5) with 10 mM NaCl. The column was washed with
15 CV and eluted using a linear gradient of 10 mM-1 M NaCl.
Fractions were analyzed by SDS-PAGE Coomassie and West-
ern blotting with anti-LDLR (ab30532, Abcam) or anti-His
antibody (A00186, GenScript). Purified proteins were quanti-
fied by BCA protein assay kit (Thermo Scientific).
SDS-PAGEWestern blotting analysis
NuPAGENovex Bis-Tris 4–12% gels were usedwith transfer
to nitrocellulose membranes for 90 min (0.45 m, Bio-Rad)
200 V. The blots were blocked in 5% skimmed milk in TBS-T
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andwashed three times in TBS-T prior to overnight incubation
at 4 °C with rabbit polyclonal anti-LDLR antibody (ab30532,
Abcam) or rabbit polyclonal anti-calnexin antibody (1:2,000)
(Enzo Life Sciences). The blots were developed with ECL
(Pierce catalog no. 32106, Thermo Scientific) after incubation
with horseradish peroxidase-conjugated secondary antibody
(Dako) for 1 h. Calnexin was used to normalize.
Metabolic labeling and immunoprecipitation
HepG2WT andGALNT11 KO cells were cultured in methi-
onine and cysteine-free RPMI 1640 (Gibco)media containing 2
mmol/liter L-glutamine for 30 min, before replacement of the
same medium containing 0.1 mCi/ml Promix ([35S]methio-
nine/[35S]cysteine) (PerkinElmer Life Sciences). For pulse-
chase, cells were labeled for 30 min and chased for 0–6 h in
complete RPMI 1640mediumcontaining 5mMmethionine and
cysteine. For co-immunoprecipitation the LDL receptor was
immunoprecipitated overnight at 4 °C using a polyclonal anti-
LDLR antibody (ab30532, Abcam) and protein G–Sepharose
(Amersham Biosciences). The immunoprecipitate was analyzed
byNuPAGE after incubation in LDS sample buffer (Invitrogen)
for 10 min at 95 °C. The bands were quantified using a Phos-
phorImager (STORM 840, Molecular Dynamics) and Image-
Quant software (Molecular Dynamics).
LDLR functional assays
The cells were cultured in 24-well plates and used at 60%
confluence. CHO cells were cultured with EX CELL CD
CHO fusion medium (Sigma) with 2% glutamine. HepG2 and
HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% FBS, and 1 day before FBS was substi-
tuted with 10% lipoprotein-deficient serum (LPDS) (Alfa
Aesar). The cells were incubated for 4 h at 4 °C for binding and
37 °C for uptake with different concentrations of FITC-LDL
(54) or DiI-LDL (Alfa Aesar), followed by washing twice in PBS
with 1% BSA, fixation in 4% formaldehyde for 10 min, and
washing twice with PBS with 1% BSA. FITC-LDL was analyzed
by FACS in a LSR-II flow cytometer (Beckman Coulter) with
10,000 events acquired for data analysis, and the results were
expressed as the mean fluorescence of activated gated cells,
selected in a forward versus side scatter window. DiI-LDL
was analyzed with cells mounted in ProLong Gold antifade re-
agent (4,6-diamino-2-phenylindole) (Invitrogen) using a
Zeiss Axioskop 2 plus with an AxioCam MR3. Bit depth and
pixel dimensions were 36 bits and 1,388 1,040 pixels, respec-
tively. Analysis of FITC-VLDL was performed as described for
LDL (54). All measurements have been performed in triplicate.
Competition assays with secreted LDLR constructs were per-
formed with 20 g/ml FITC-LDL or DiI-LDL preincubated
with the indicated concentrations of secreted LDLR constructs
at 37 °C before addition to cells for 4 h.
Neuraminidase pretreatment
The cells for binding and uptake assays were incubated with
Clostridium perfringens neuraminidase (Sigma, N3001) diluted
in PBS to a final concentration of 0.1 unit/ml at 37 °C for 4 h,
followed by washing twice with in medium containing LPDS.
Controls for neuraminidase included staining with biotinylated
PNA (B-1073) and biotinylated Maackia amurensis lectin II
(B-1265) lectins followed by Alexa Fluor 488–conjugated
streptavidin (Life Technologies, S32354).
LDLR expression
HepG2 cells cultured in medium with LPDS for 24 h, resus-
pended in PBSwith 1%BSA, blocked 30minwith PBSwith 10%
FBS, washed twice with PBS with 1% BSA, and incubated with
rabbit polyclonal anti-LDLR (1:100; 3 mg/liter; Ab30532) for
1 h at room temperature followed by FITC-conjugated swine
anti-rabbit IgG (1:100; Dako) and analysis in a LSR-II flow
cytometer.
Direct LDL-binding assays
A modified ELISA binding assay with purified sLDLR and
LA1–4 coated in 96-well plates in 10mMTris-HCl (pH 7.4) and
50 mM NaCl, 2 mM CaCl2 (buffer A) was used (55). The plates
were blocked with 5% BSA and incubated with freshly purified
human LDL in buffer A for 2 h at room temperature, before
washing four times with buffer A and once with buffer A con-
taining 0.1% Tween 20, followed by incubation with goat poly-
clonal anti-apolipoprotein B (Abcam, UK) for 1 h, peroxidase-
conjugated mouse anti-goat IgG (Thermo Scientific) for 1 h,
and development with 2,2-azino-bis(3-ethylbenzothiazoline-
6-sulfonic acid) substrate (Sigma–Aldrich) and photometric
quantification at 405 nm. All data were corrected for unspecific
binding and relativized to maximum, and EC50 values were
extracted from binding curves after fitting the data to a five-
parameter logistic equation (SigmaPlot 13.0; Systat Software
Inc.). In control experiments, mouse monoclonal anti-LDL
receptor (PROGEN) and horse anti-mouse horseradish perox-
idase-linked secondary antibody (Cell Signaling Technology)
were used to detect the amount of LDLR fragments bound to
plate and calculate the surface coverage percentage. Experi-
ments were carried out at two surface subsaturating coverage
percentages and [L]  [R] conditions, obtaining the same
binding values.
Recombinant expression of Drosophila pgant35A and Lpr2-E
The full coding region ofDrosophila melanogaster pgant35A
was derived from pUAST-pgant35A (56) and subcloned into
pcDNA3 (Invitrogen) to generate pcDNA3-pgant35A. The
ORF of D. melanogaster lpr2E with a C-terminal 3 HA tag in
pUAST-lpr2E was kindly provided by Joaquim Culi (Sevilla,
Spain; Ref. 23) and used to generate pcDNA3-lpr2E. The
pcDNA3-pgant35A construct was expressed in CHO Galnt11
KO cells (1C8 clone) by electroporation and G418 selection,
and stable clones were identified by PCR with primers
PCDNAFOR and dT1-KPS (5-CGATTCGCCAGTGGTAAT-
GCTGGC-3). The pcDNA3-lpr2E construct was stably
expressed in CHOWT, CHO Galnt11 KO, and CHO Galnt11
KO with expression of pgant35A, using electroporation and
Zeocin selection. Stable clones were screened by immunocyto-
chemistry and Western blotting analysis using a monoclonal
anti-HA antibody (Santa Cruz).
Analysis of recombinant shed Drosophila Lpr2-E
Culture medium from CHO cells stably expressing full cod-
ing C-terminal HA-tagged Drosophila Lpr2-E construct was
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diluted twice in 175 mM Tris (pH 7.5) and loaded twice onto a
0.8-ml Jacalin lectin column, followed by 20 CV washing in
the same buffer and 2 CV washing with 50 mM ammonium
bicarbonate added. Bound O-glycoproteins were eluted by
heating the lectin slurry in 0.1% RapiGest. The eluate was
heated for 10 min at 80 °C, reduced with 20 mM DTT at 60 °C
for 45 min, alkylated with 40 mM iodoacetamide in 50 mM
ammonium bicarbonate at room temperature for 35 min fol-
lowed by addition of 20 mM DTT to terminate alkylation, and
finally digested with trypsin (1 g/sample) (Roche) at 37 °C
overnight. Digests were treatedwith concentratedTFA at 37 °C
for 30 min, cleared by centrifugation, purified on C18 Sep-Pak
(Waters), and lyophilized. Each sample was dissolved in 0.1%
TFA and submitted to LC-MS and high-energy collision disso-
ciation/electron transfer dissociation–MS/MS.
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